Biotech-Pharma (Therapy)

Compounds to induce satiation and control food intake, modulate body fat and regulate the lipid metabolism

An Andalusian Public Healthcare System (SSPA) research team has discovered a new series of **compounds to induce satiation, control food intake and modulate metabolic effects for use as a pharmacological tool in the treatment and/or prevention of metabolic and cardiovascular diseases.**

Oficina de TRANSFERENCIA DE TECNOLOGÍA
Sistema Sanitario Público de Andalucía



Description

Cases of obesity and related diseases are increasing, which is a major problem for healthcare systems. Existing treatments are currently no more effective than dieting and there has been little success in developing drugs to induce a reduction of body weight in a sustained way with few side effects.

The research team has developed a series of compounds that exhibit an affinity for peroxisome proliferator-activated receptors (PPAR) and, therefore, modulate the actions regulated by them, such as inducing satiation, controlling food intake, and modulating metabolic effects. They consequently represent a **new therapeutic alternative in the treatment and/or prevention of metabolic and cardiovascular diseases.**

The technology developed by the group also includes the preparation procedure for the compound and its method of use.

Advantages

The **proof of concept** conducted through *in vivo* experiments showed that:

1. It successfully **reduced food intake by 50%**: it showed an effect **120 minutes after administration** which **disappeared after 240 minutes afterwards**. This trait means that the compound tested is especially **interesting for acute administration**.
2. In addition to reducing food intake by some 50%, it has **a sustained effect for 240 minutes** following administration; it also **continues to have an effect 24 hours** afterwards. This makes the assay compound **interesting for chronic administration.**

Intellectual Property

This technology is protected by patent.

Aim

The research group is looking for a license or a collaboration agreement.

Classification

Area: Biotech-Pharma (Therapy)
Technology: Small molecules
Pathology: Metabolic diseases and Endocrinology

JUNTA DE ANDALUCIA
CONSEJERÍA DE IGUALDAD, SALUD Y POLÍTICAS SOCIALES

FIMABIS
FUNDACIÓN PUBLICA ANDALUZA PARA LA INVESTIGACIÓN DE MÁLAGA EN BIOMEDICINA Y SALUD

Avda. Jorge Luis Borges, 15. bloque 3, 3° 29010. Málaga. SPAIN
☎+34 951 440 260 🖷 +34 951 440 263 ☞isabel.guerrero@fimabis.org
www.fimabis.org